Regulatory Updates
Page 1 • 12 itemsTrack global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
EMA Conditional Marketing Authorizations: Evolving Framework & PRAC Safety Insights
This article delves into the evolving framework of EMA Conditional Marketing Authorizations and highlights PRAC's safety insights for drug XYZ in cancer therapy.
MHRA Divergence from EMA: What You Need to Know for EU Market Access
This article explores the key differences between MHRA and EMA regulations, focusing on how they affect market access for drugs like XYZ in the EU.
EU HTA Regulation: Impact on Market Access for Novel Therapies in DE, FR, IT
This article examines how the EU HTA Regulation affects market access for innovative therapies, focusing on the implications for drugs like XYZ in Germany, France, and Italy.
EMA Conditional Marketing Authorizations: 5-Year Review of Oncology Drug Approvals
This article reviews the EMA's conditional marketing authorizations over the past five years, focusing on oncology drugs and their impact on cancer treatment accessibility.
EMA Conditional Marketing Authorizations: What You Need to Know
Explore the key aspects of EMA Conditional Marketing Authorizations, focusing on drug XYZ for ABC treatment, and understand its implications for the industry.
MHRA vs EMA Approval Pathways: Strategic Implications for EU Market Access
This article delves into the differences between MHRA and EMA approval pathways, highlighting their strategic implications for drug XYZ's market access in the EU.
EMA Conditional Marketing Authorizations: What You Need to Know
Explore the essentials of EMA Conditional Marketing Authorizations, focusing on drug XYZ for rare diseases and the implications for pharmaceutical companies.
EMA CHMP Recommends Five New Medicines Including Tolebrutinib (Cenrifki) for Approval in April 2026
European Medicines Agency's CHMP committee recommended five new medicines for approval in April 2026, including tolebrutinib (Cenrifki) for multiple sclerosis treatment.
EU Pharmaceutical Legislation Reform: Impact on Biosimilar Market Access & Competition
The recent EU pharmaceutical legislation reform aims to enhance biosimilar market access and competition, significantly affecting drugs like Adalimumab for autoimmune treatments.
EU Pharmaceutical Legislation Reform: Impact on Orphan Drugs & Market Exclusivity
This article delves into the EU pharmaceutical legislation reform and its implications for orphan drugs, focusing on market exclusivity and patient access.
MHRA Post-Brexit Drug Approval vs EMA Centralized Procedure: Key Insights
This article delves into the key insights of MHRA's post-Brexit drug approval process versus the EMA's centralized procedure, focusing on drug XYZ for cancer.
Conditional Marketing Authorizations EU: 5-Year Review of Benefits & Risks
This article reviews the benefits and risks of Conditional Marketing Authorizations in the EU, focusing on drug XYZ's impact on condition ABC over the past five years.